SCHEMBL6791397

SCHEMBL6791397

COc1cc(NC(=O)/C=C(/C)c2ccc(Br)c(Br)c2)c(C(=O)O)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
LTB4R Q15722 1/20 0.51
KDM4E B2RXH2 7/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 1/20 0.50
RCE1 Q9Y256 1/20 0.50
TERT O14746 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
AKR1C4 P17516 1/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
GFER P55789 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA7 P43166 1/20 0.46
LCK P06239 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6791818 0.92 LTB4R (0.48) MAPTLTB4RKDM4EALDH1A1HPGD
SCHEMBL6786762 0.91 KDM4E (0.53) MAPTLTB4RKDM4EALDH1A1HPGD
SCHEMBL6792144 0.90 MAPT (0.49) MAPTLTB4RKDM4EALDH1A1HPGD
SCHEMBL6785190 0.90 KDM4E (0.51) MAPTLTB4RKDM4EALDH1A1HPGD
SCHEMBL4028323 0.84 KDM4E (0.60) MAPTLTB4RKDM4EALDH1A1HPGD
SCHEMBL6783723 0.84 KDM4E (0.46) MAPTLTB4RKDM4EALDH1A1HPGD
SCHEMBL6786628 0.83 TERT (0.58) MAPTLTB4RKDM4EALDH1A1HPGD
SCHEMBL4021468 0.83 TERT (0.71) MAPTLTB4RKDM4EALDH1A1HPGD
SCHEMBL6786854 0.82 TERT (0.57) MAPTLTB4RKDM4EALDH1A1HPGD
SCHEMBL6790898 0.81 KDM4E (0.50) MAPTLTB4RKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US claimed
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 MAPT 1221/4885LTB4R 3433/4885KDM4E 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.